Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + bortezomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Cyclophosphamide + bortezomib + dexamethasone is a three-drug combination regimen used primarily as induction therapy for multiple myeloma. Bortezomib is a first-in-class proteasome inhibitor that blocks the 26S proteasome, leading to accumulation of proteins within the cell and subsequent apoptosis of malignant plasma cells. Cyclophosphamide is an alkylating agent (chemotherapy) that destroys rapidly dividing cells by cross-linking DNA strands and inhibiting DNA replication. Dexamethasone is a synthetic glucocorticoid steroid with anti-inflammatory and immunosuppressive properties; in this context, it helps kill myeloma cells and reduce inflammation associated with cancer or its treatment. This combination has demonstrated significant efficacy as both induction and consolidation therapy in newly diagnosed or relapsed/refractory multiple myeloma patients[1][2][3][4][6].
- Brand names
- CyBorDVCDCVD
- Other names
- CyBorD regimenVCD regimencyclophosphamide, bortezomib, and dexamethasone
02
Targets
GR (Glucocorticoid receptor)DNAPSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on cyclophosphamide + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + bortezomib + dexamethasone.